AIB1 as an Independent Prognostic Marker in Hepatocellular Carcinoma After Hepatic Resection

Journal of Gastrointestinal Surgery

Volumn 16, Issue 2, 2012, Pages 356-360

  Song, Jun Min ^a   Lu, Min ^b   Liu, Fang Fang ^a   Du, Xiao Juan ^b   Xing, Bao Cai ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Amplified in breast cancer 1; Hepatocellular carcinoma; Prognosis

Indexed keywords

ALPHA FETOPROTEIN; NCOA3 PROTEIN, HUMAN; STEROID RECEPTOR COACTIVATOR 3; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL; SURVIVAL RATE;

ADULT; AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NUCLEAR RECEPTOR COACTIVATOR 3; PROGNOSIS; SURVIVAL ANALYSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84856220813     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-011-1762-9     Document Type: Article

References (31)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74-108.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57: 43-66.
3. Forner A, Reig M, Bruix J. Alpha-fetoprotein for hepatocellular carcinoma diagnosis: the demise of a brilliant star. Gastroenterology. 2009; 137: 26-9.
4. Cabrera R, Nelson DR. Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther. 2010; 31: 461-76.
5. Moribe T, Iizuka N, Miura T, et al. Methylation of multiple genes as molecular markers for diagnosis of a small, well-differentiated hepatocellular carcinoma. Int J Cancer. 2009; 125: 388-97.
6. Marrero JA, Welling T. Modern diagnosis and management of hepatocellular carcinoma. Clin Liver Dis. 2009; 13: 233-47.
7. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005; 42: 1208-36.
8. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003; 362: 1907-17.
9. Yang LY, Lu WQ, Huang GW, et al. Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma. BMC Cancer. 2006; 6: 110.
10. Shi YH, Ding WX, Zhou J, et al. Expression of X-linked inhibitor of apoptosis protein in hepatocellular carcinoma promotes metastasis and tumor recurrence. Hepatology. 2008; 48: 497-507.
11. Pan HW, Qu YH, Peng SY, et al. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer. 2003; 98: 119-27.
12. Kubo S, Hirohashi K, Tanaka H, et al. Effect of viral status on recurrence after liver resection for patients with hepatitis B virus-related hepatocellular carcinoma. Cancer. 2000; 88: 1016-24.
13. Park JH, Koh KC, Choi MS, et al. Analysis of risk factors associated with early multinodular recurrences after hepatic resection for hepatocellular carcinoma. Am J Surg. 2006; 192: 29-33.
14. Anzick SL, Kononen J, Walker RL, et al. AIB1, a novel estrogen receptor co-activator amplified in breast and ovarian cancer. Science. 1997; 277: 965-8.
15. Gnanapragasam VJ, Leung HY, Pulimood AS, et al. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. Br J Cancer. 2001; 85: 1928-36.
16. Tanner MM, Grenman S, Koul A, et al. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res. 2000; 6: 1833-9.
17. Xu FP, Xie D, Wen JM, et al. SRC-3/AIB1 protein and gene amplification levels in human esophageal squamous cell carcinomas. Cancer Lett. 2007; 245: 69-74.
18. Sakakura C, Hagiwara A, Yasuoka R, et al. Amplification and over-expression of the AIB1 nuclear receptor co-activator gene in primary gastric cancers. Int J Cancer. 2000; 89: 217-23.
19. Henke RT, Haddad BR, Kim SE, et al. Overexpression of the nuclear receptor coactivator AIB1 (SRC-3) during progression of pancreatic adenocarcinoma. Clin Cancer Res. 2004; 10: 6134-42.
20. Grivas PD, Tzelepi V, Sotiropoulou-Bonikou G, et al. Estrogen receptor alpha/beta, AIB1, and TIF2 in colorectal carcinogenesis: do coregulators have prognostic significance? Int J Colorectal Dis. 2009; 24: 613-22.
21. Luo JH, Xie D, Liu MZ, et al. Protein expression and amplification of AIB1 in human urothelial carcinoma of the bladder and overexpression of AIB1 is a new independent prognostic marker of patient survival. Int J Cancer. 2008; 122: 2554-61.
22. Liu MZ, Xie D, Mai SJ, et al. Overexpression of AIB1 in nasopharyngeal carcinomas correlates closely with advanced tumor stage. Am J Clin Pathol. 2008; 129: 728-34.
23. Wang Y, Wu MC, Sham JS, et al. Prognostic significance of c-myc and AIB1 amplification in hepatocellular carcinoma. A broad survey using high-throughput tissue microarray. Cancer. 2002; 95: 2346-52.
24. Xu Y, Chen Q, Li W, et al. Overexpression of transcriptional coactivator AIB1 promotes hepatocellular carcinoma progression by enhancing cell proliferation and invasiveness. Oncogene. 2010; 29: 3386-97.
25. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48, 900 necropsies. Cancer. 1954; 7: 462-503.
26. Gojis O, Rudraraju B, Alifrangis C, et al. The role of steroid receptor coactivator-3 (SRC-3) in human malignant disease. Eur J Surg Oncol. 2010; 36: 224-9.
27. Mussi P, Yu C, O'Malley BW, et al. Stimulation of steroid receptor coactivator-3 (SRC-3) gene overexpression by a positive regulatory loop of E2F1 and SRC-3. Mol Endocrinol. 2006; 20: 3105-19.
28. Torres-Arzayus MI, Font de Mora J, Yuan J, et al. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell. 2004; 6: 263-74.
29. Harigopal M, Heymann J, Ghosh S, et al. Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome. Breast Cancer Res Treat. 2009; 115: 77-85.
30. He LR, Liu MZ, Li BK, et al. Overexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma. Cancer Sci. 2009; 100: 1591-6.
31. He LR, Zhao HY, Li BK, et al. Overexpression of AIB1 negatively affects survival of surgically resected non-small-cell lung cancer patients. Ann Oncol. 2010; 21: 1675-81.